Christopher Cabell - 21 Feb 2025 Form 3/A - Amendment Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role: President & Head of R&D
Signature: /s/ Mark Iwicki, attorney-in-fact
Issuer symbol: IKT
Transactions as of: 21 Feb 2025
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 28 Aug 2025, 19:52:09 UTC
Date Of Original Report: 25 Feb 2025
Previous filing: 22 May 2023
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cabell Christopher	President & Head of R&D	1000 N. WEST STREET, SUITE 1200, WILMINGTON	/s/ Mark Iwicki, attorney-in-fact	28 Aug 2025	0001814928

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	IKT	Common Stock						1,014,846	21 Feb 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 3 amendment is being filed solely to include shares of common stock which were inadvertently omitted from the original Form 3 filed by the Reporting Person on February 25, 2025.
F2	Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 169,141 shares vested on the Closing Date, 507,423 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 338,282 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 338,282 shares shall be forfeited.

Content

This Form 3 amendment is being filed solely to include shares of common stock which were inadvertently omitted from the original Form 3 filed by the Reporting Person on February 25, 2025.

Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 169,141 shares vested on the Closing Date, 507,423 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 338,282 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 338,282 shares shall be forfeited.